News & Events

Seventure Partners Launches New €120m ‘Health For Life Capital’ Innovation Fund

Seventure Partners Launches New €120m ‘Health For Life Capital’ Innovation Fund

Paris, France – 20 January 2014 − Seventure Partners, one of Europe’s leaders in innovation financing, has announced the launch of its new fund: Health for Life Capital.

This €120m fund is dedicated to health, connected health, nutrition, and the recent game-changing discoveries related to the microbiome.  It will invest in innovative companies with high growth potential mainly in Europe but will also look to expand in North America and Asia.

Appointed CEO in October 2011, Isabelle de Cremoux led this fundraising. She has been heading the Life Science team since 2001 and is the force behind the strategic positioning of Seventure Partners in these fields.

Seventure Partners is acknowledged as a world leader in financing the converging domains of medicine and foodscience. It has expertise in the microbiome and its applications which spans the food, pharmaceutical, medical technologies and diagnostics industries.

Seventure's team has built a unique portfolio of companies operating in the microbiome and nutrition sectors, including Enterome, LNC, Polaris, Nutrionix, Fluxome (sold to Evolva), and in the field of connected health, including Mauna Kea, Cardiosecure-PMS, Acarix, Impeto, Biancamed (sold to Resmed).

Isabelle de Cremoux, CEO at Seventure Partners, said of the fund: “We are proud to work with prestigious industry champions as Danone, Tereos and Tornier. The close cooperation we have established with these investors will boost the financial performance of Health For Life Capital. We also have attracted financial investors like Natixis and Unigrains.“

Seventure's industry partners, Danone and Tereos display a strong innovative, oriented strategy. They are world leaders and pioneers in the convergence of food and health.

Health For Life Capital has already been approached by numerous pharmaceutical laboratories, diagnostics and ingredient companies as well as financial investors. Seventure Partners is thus anticipating new future closings in the coming months.

Notes to Editors

About Seventure Partners

Being one of the leading venture capital firms in Europe, Seventure manages more than €500m and invests since 1997 in innovative businesses with high growth potential in Digital Technologies in France and Germany, and in Life Sciences all over Europe.

In Life Sciences our four preferred sectors are biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology and cleantech, and microbiome, lifestyle healthcare, personalised medicine and nutrition and food. We also consider investments in diagnostics, biomarkers, drug delivery systems, and services.

A typical investment ranges from €500k to €10m per round, up to €20m per company, from early to later stage.
Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information, visit:


Issued for and on behalf of Seventure.

To contact a member of the Seventure team at College Hill, email

back to news


Melanie Toyne-SewellManaging Partner